Development of NGS Target Enrichment Solutions for Clinical Applications

21 Feb 2023 | 09:00 - 13:00hrs SGT

Theatrette 2 @ Matrix, Biopolis (applicable for those based in Singapore)

Seminar Description

Advances in Next Generation Sequencing (NGS) are driving improvements in detection, treatment and routine monitoring of cancer. Faster and more accurate assays will ultimately lead to better outcomes for patients.

Hear from key opinion leaders in the cancer research and clinical oncology field, and learn how they overcome their research hurdles using Twist’s robust and effective NGS target enrichment solutions.

For those joining us at the live event at Biopolis on 21 February, lunch will be provided after the seminar for you to network with industry leaders.

For those outside of Singapore, please register below and we will send you the recording after 21 February. 

Time Topic
09:00 - 09:30 Registration Open
09:30 - 09:40 Opening
09:40 - 10:15 Presentation by Richard Tothill Comprehensive genomic profiling including DNA methylation analysis for diagnostically challenging cancers of unknown primary
10:15 - 10:50 Presentation by John Chambers DNA methylation signatures for cardiovascular and metabolic disease
10:50 - 11:10 Tea-Break
11:10 - 11:45 Presentation by Sebastian Lunke Screening, diagnosis, prediction – Genomic data for the whole of life
11:45 - 12:05 Presentation by Ananth Bommakanti Writing The Future with Twist Bioscience
12:05 - 12:35 Panel Discussion
12:35 - 12:40 Closing
12:40 - 14:00 Networking Lunch

Richard Tothill

Associate Professor, University of Melbourne Centre for Cancer Research
Presentation Title: Comprehensive genomic profiling including DNA methylation analysis for diagnostically challenging cancers of unknown primary

Associate Professor Richard Tothill is a group leader within the University of Melbourne Centre for Cancer Research and heads the Rare Disease Oncogenomics Laboratory. His work involves understanding the genomic pathology of rare cancers, development of diagnostic methods and implementation clinical genomics for precision medicine. He has been an early adopter of genomic technologies including next-generation DNA sequencing and bulk and single-cell gene-expression profiling methods. He currently co-leads the national Solving Unknown Primary Cancer (SUPER) suite of studies and is principal investigator for the MRFF funded SUPER-NEXT study involving deployment of clinical whole-genome sequencing and the application of liquid biopsy testing for patients with cancer of unknown primary.

John Chambers

Chief Scientific Officer, Precision Health Research, Singapore (PRECISE)
Presentation Title: DNA methylation signatures for cardiovascular and metabolic disease

Professor John Chambers is Chief Scientific Officer (CSO) of PRECISE, the central entity established to implement Phase II of Singapore’s National Precision Medicine strategy. Prof Chambers is the lead investigator of the PRECISE-SG100K population cohort study, a multi-institutional effort that aims to study the genetic makeup of 100,000 healthy Singaporeans and specific disease cohorts. The genetic data will be integrated with detailed lifestyle, environmental, and clinical data to yield rich insights into factors that contribute to Asian diseases and conditions.
Prof Chambers’ own research focuses on identification of mechanisms underlying the high rate of cardiovascular disease and diabetes in Asian populations and translational research to improve prevention and control of these major diseases. He has been closely involved in large-scale prospective population studies in Europe, South Asia and Singapore. His research has contributed to the discovery of novel genetic and epigenetic pathways associated with coronary heart disease, type-2 diabetes, obesity, and related metabolic disturbances implicating new molecular pathways underlying these diseases.
As Professor of Cardiovascular Epidemiology at LKCMedicine, Prof Chambers will continue to focus on identifying new strategies for prediction and prevention of cardiovascular disease and diabetes. He also aims to aspire a new generation of researchers who will continue his efforts in identifying novel ways to predict and prevent cardiovascular diseases and diabetes. He hopes to achieve these through the research networks he has established in the region, the research platform at LKCMedicine and partner healthcare organisations.

Sebastian Lunke

Head of the Division of Genetics and Genomics, Victorian Clinical Genetics Services
Presentation Title: Screening, diagnosis, prediction - Genomic data for the whole of life

Associate Professor Sebastian Lunke is a Clinical Scientist, and the Head of the Division of Genetics and Genomics at the Victorian Clinical Genetics Services (VCGS), where he is currently overseeing the genetic, genomic and cytogenetic testing laboratories as well as assay development and translation activities. He is also the Innovation Lead for the Genomics Stream at the Murdoch Children’s Research Institute. Seb has over a decade of experience in medical science and translational research and was the first scientist to be admitted into the Royal College of Pathologists of Australasia’s Faculty of Science training program for Clinical Scientists. Since joining VCGS he has enabled and led a wide range of research projects across a range of disciplines, all with a common theme of implementation new technology and techniques into clinically accredited practise. He has co-authored over 70 publications with over 2500 citations, and is currently an investigator on genomics research grants worth approximately AUD 50M.

Ananth Bommakanti

Sr. Field Applications Scientist, APAC, Twist Bioscience
Presentation Title: Writing the Future with Twist Bioscience

Ananth earned his PhD in Molecular and Cellular Biology from University of Maryland Baltimore. During his tenure as Postdoctoral fellowship at Yale University, USA and later at Temasek Life Science Laboratory Singapore he worked on developing NGS-based Diagnostics for early cancer detection, assessing Radiation poisoning, and biomarker identification for neurological disease progression. He has been with Twist Bioscience from past 4 years as a Sr. Bioinformatics and NGS, Field Application Scientist, helping customers accelerate today’s NGS-based research using the TWIST range of NGS products.
©. All Rights Reserved Twist Bioscience.